Chinese expert consensus on Co-Ablation System for the treatment of primary liver cancer （2023 edition） / 临床肝胆病杂志

ABSTRACT

@#Clinically， the recurrence and metastasis of liver cancer after local ablation therapy have been the main factors affecting the long-term survival of patients with liver cancer. As a new generation of composite cryoablation and thermal ablation system， Co-Ablation System creatively integrates the advantages of profound hypothermia cryoablation and thermal ablation， which can maximize the release of tumor antigen while completely destroying liver cancer in situ， thus， the purpose of controlling liver cancer recurrence and metastasis can be achieved. Co-Ablation System treatment is usually carried out through percutaneous puncture under ultrasound or CT guidance. The selection of local anesthesia or general anesthesia is based on the size and location of the liver cancer. Co-Ablation System treatment is mainly suitable for single tumor with diameter <5 cm and multiple tumors（≤3 tumor lesions） with a maximum diameter <3 cm. After ablation， protection of liver function and symptomatic treatment are employed according to patient’s condition. About one month after ablation， MRI or contrast-enhanced CT examination is performed to evaluate the therapeutic efficacy， then， the patients are followed up regularly. In order to standardize the application of Co-Ablation System in treating liver cancer， the Committee of Minimally Invasive Therapy in Oncology and the Committee of Ablation Therapy in Oncology， Chinese Anti-Cancer Association， have organized domestic experts engaged in liver cancer ablation therapy to make a professional and in-depth discussion and to compose this expert consensus on Co-Ablation System for the treatment of primary liver cancer.